✦ LIBER ✦

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL

✍ Scribed by Pfreundschuh, Michael (author);Trümper, Lorenz (author);Kloess, Marita (author);Schmits, Rudolf (author);Feller, Alfred C. (author);Rübe, Christian (author);Rudolph, Christian (author);Reiser, Marcel (author);Hossfeld, Dieter K. (author);Eimermacher, Hartmut (author);Hasenclever, Dirk (author);Schmitz, Norbert (author);Loeffler, Markus (author)

Book ID: 121760219
Publisher: American Society of Hematology
Year: 2004
Tongue: English
Weight: 107 KB
Volume: 104
Category: Article
ISSN: 0006-4971
DOI: 10.1182/blood-2003-06-2095

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Two-weekly or 3-weekly CHOP chemotherapy

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL

✍ Pfreundschuh, Michael (author);Trümper, Lorenz (author);Kloess, Marita (author); 📂 Article 📅 2004 🏛 American Society of Hematology 🌐 English ⚖ 107 KB

Six versus eight cycles of bi-weekly CHO

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

✍ Michael Pfreundschuh; Joerg Schubert; Marita Ziepert; Rudolf Schmits; Martin Moh 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 283 KB

Six versus eight cycles of bi-weekly CHO

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

✍ Michael Pfreundschuh; Joerg Schubert; Marita Ziepert; Rudolf Schmits; Martin Moh 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 283 KB

Equitoxicity of bolus and infusional eto

Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone)

✍ Carsten Zwick; Josef Birkmann; Norma Peter; Heinrich Bodenstein; Roland Fuchs; M 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 259 KB

CHOP-like chemotherapy with or without r

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

✍ Michael Pfreundschuh; Evelyn Kuhnt; Lorenz Trümper; Anders Österborg; Marek Trne 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 853 KB

Rituximab, bendamustine, and lenalidomid

Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial

✍ Hitz, F.; Fischer, N.; Pabst, Th.; Caspar, C.; Berthod, G.; Eckhardt, K.; Berard 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 160 KB